Inferra AI / Company / LFST
Lifestance Health Group, Inc.
LFST · Health Care
Last earnings Aug 6, 2026
Key results
Revenuequarter
$345.3 million
Revenue of $345.3 million increased 11% compared to
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
revenue of $312.3 million •
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Free cash flowquarter
$56.6 million
Free Cash Flow of positive $56.6 million in the second quarter •
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Also, we delivered exceptionally strong Free Cash Flow of $57 million, our highest in any quarter to date, which provides additional capacity to invest further in the business.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenue grew 11% to $345.3 million.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenue of $345.3 million increased 11% year-over-year Total Clinicians of 7,708 increased +11% Y/Y
SEC original ↗Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Clinicians Q2 2025 Results Adjusted EBITDA (in $M) Center Margin (in $M) Revenue (in $M) 9.2% 9.8% 31.3% 31.4% Center Margin (% of total revenue) +11% +11% +11% +19% Adj.
SEC original ↗Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
EBITDA (% of total revenue) Center Margin (in $M) Revenue (in $M) Center Margin (% of total revenue) 31.3% 32.1% 33.6% 33.0% 31.4% 9.2% 9.8% 10.1% 10.4% 9.8% Note: See reconciliation of GAAP to non-GAAP measures and of prior period reported clinicians in the Appendix to this presentation.
SEC original ↗Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 7, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $345.3 million | — | — |
| Free cash flow | $56.6 million | — | — |
Guidance · company-stated
Direction: Raised
“We delivered double-digit organic revenue growth along with 10% Adjusted EBITDA margins, and are raising our full year guidance midpoint for Adjusted EBITDA by $5 million.”
“2025 Guidance LifeStance is providing the following outlook for 2025: • The Company is reiterating full year revenue of $1.40 billion to $1.44 billion; raising Center Margin to $441 million to $465 million; and raising Adjusted EBITDA to $140 million to $150 million.”
Classified from the release's primary full-year outlook statement.
Cash flow & capex
Capital allocation
The Company ended the second quarter with cash of $188.9 million and net long-term debt of $272.9 million.
The 2024 Credit Agreement established a senior secured term loan facility of $ 290,000 and a senior secured revolving loan facility of up to $ 100,000 .
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue -98.6% computed from stated figures
Event summary
Lifestance Health Group, Inc. Q2 2025 — Revenue of $345.3 million increased 11% compared to
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “We delivered double-digit organic revenue growth along with 10% Adjusted EBITDA margins, and are raising our full year guidance midpoint for Adjusted EBITDA by $5 million.”
Revenue: “2025 Guidance LifeStance is providing the following outlook for 2025: • The Company is reiterating full year revenue of $1.40 billion to $1.44 billion; raising Center Margin to $441 million to $465 million; and raising Adjusted EBITDA to $140 million to $150 million.”
Revenue — Raised (“raising”)
“We delivered double-digit organic revenue growth along with 10% Adjusted EBITDA margins, and are raising our full year guidance midpoint for Adjusted EBITDA by $5 million.”
Revenue — Raised (“raising”)
“2025 Guidance LifeStance is providing the following outlook for 2025: • The Company is reiterating full year revenue of $1.40 billion to $1.44 billion; raising Center Margin to $441 million to $465 million; and raising Adjusted EBITDA to $140 million to $150 million.”
Classified from the release's primary full-year outlook statement.
Capital allocation
The Company ended the second quarter with cash of $188.9 million and net long-term debt of $272.9 million.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The 2024 Credit Agreement established a senior secured term loan facility of $ 290,000 and a senior secured revolving loan facility of up to $ 100,000 .
SEC original ↗Lifestance Health Group, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The loans under the term loan facility bear interest at a rate per annum equal to (x) term SOFR (which term SOFR is subject to a minimum of 0.00 %) plus an applicable margin of 3.00 % subject to stepdowns based on leverage-based metrics or (y) an alternate base rate (which will be the highest of (i) the prime rate, (ii) 0.50 % above the federal funds effective rate and (iii) one-month term SOFR (which term SOFR is subject to a minimum of 0.00 %) plus 1.00 %) plus an applicable margin of 2.00 % subject to stepdowns based on leverage-based metrics.
SEC original ↗Lifestance Health Group, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company was in compliance with all debt covenants at June 30, 2026 and December 31, 2025.
SEC original ↗Lifestance Health Group, Inc. — 10-Q Quarterly report10-QAug 6, 2026
11 Long-term debt consists of the following: June 30, 2026 December 31, 2025 Term loan $ 275,500 $ 282,750 Less: Current portion of long-term debt ( 14,500 ) ( 14,500 ) Less: Unamortized discount and debt issue costs (1) ( 2,009 ) ( 2,323 ) Total Long-Term Debt, Net of Current Portion and Unamortized Discount and Debt Issue Costs $ 258,991 $ 265,927 (1) The unamortized debt issue costs related to long-term debt are presented as a reduction of the carrying amount of the corresponding liabilities on the unaudited consolidated balance sheets.
SEC original ↗Lifestance Health Group, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Unamortized debt issue costs related to revolving loans are presented within other noncurrent assets on the unaudited consolidated balance sheets.
SEC original ↗Lifestance Health Group, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
, complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
(3) Strategic initiatives consist of expenses directly related to a multi-phase system upgrade in connection with our recent and significant expansion.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Strategic initiatives represents costs, such as third-party consulting costs and one-time costs, that are not part of our ongoing operations related to these enterprise-wide systems.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
(4) Real estate optimization and restructuring charges consist of cash expenses and non-cash charges related to our real estate optimization initiative, which included certain asset impairment and disposal costs, certain gains and losses related to early lease terminations, and exit and disposal costs related to our real estate optimization initiative to consolidate our physical footprint during 2023.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
As the decision to close these centers was part of a significant strategic project driven by a historic shift in behavior, the magnitude of center closures was greater than what would be expected as part of ordinary business operations and did not constitute normal recurring operating activities.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Risks & headwinds
They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
(2) Litigation costs include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case (e.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
, complex class action litigation), (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
During each of the three and six months ended June 30, 2025 and 2024, litigation costs included cash expenses related to distinct litigation matters, including a privacy class action litigation and a compensation model class action litigation, and for the three and six months ended June 30, 2024, a securities class action litigation.
SEC original ↗Lifestance Health Group, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
These statements are subject to known and unknown uncertainties and contingencies outside of LifeStance's control and which are largely based on our current expectations and projections about future events and financial trends that we believe may affect LifeStance's financial condition, results of operations, business strategy, and prospects.
SEC original ↗Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Forecasts, assumptions, expectations, beliefs, estimates and projections involve risk and uncertainties and are subject to change based on various factors.
SEC original ↗Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Earnings deck slides
0 decks with slide viewLifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lifestance Health Group, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documentsEarnings releases
10 documentsPresentations
8 documents
Transcripts
0 documentsNo transcripts for Lifestance Health Group, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.